Track topics on Twitter Track topics that are important to you
Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located at Milton Park, near Oxford. The company traces its roots back to Avidex Limited which was founded in 1999 as a spin-out from the University of Oxford to develop technology invented by the founder and chief scientist, Dr Bent Jakobsen. Avidex was acquired in 2006 by the German company Medigene AG. In 2008, MediGene span out two independent companies based on the same core TCR enhancement technology platform; Immunocore to develop soluble protein therapeutics and Adaptimmune to develop cellular therapies. ( www.immunocore.com ).
57c Milton Park
Phone: +44 (0)1235 438600
Fax: +44 (0)1235 438601
Immunocore and the US biotech giant Genentech are building on their existing partnership to boost the clinical development of Immunocore’s immunotherapy for treating solid tumors. In the agreeme...
To co-develop Immunocore’s IMC-C103C candidate, an ImmTAC molecule targeting tumors that express the protein MAGE-A4
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Immunocore: Director, Market Access . Immunocore: As part of our new Commerci...
Immunocore’s $100 million Genentech deal gives it the runway to get to its first product approved, which it needs to justify its lofty valuation.
NewsThe first-in-human clinical trial of IMC-C103C scheduled to commence in 2019 in multiple solid tumor indications.
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Immunocore: Senior Clinical Project Manager . Immunocore: We’re looking...
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Immunocore: Associate Director, Clinical Operations . Immunocore: As the Asso...
Immunocore has dosed the first patient in a Phase I trial to investigate the safety and tolerability of IMCnyeso for...Read More... The post Immunocore doses first patient in Phase I trial of IMCnyeso...
Famotidine Tablets, USP 20 mg
Facility Maintenance Instant Hand Sanitizer HS-67
Amar ICE GEL
Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...
Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...
Adaptimmune Limited is focused on the use of T cell therapy to treat HIV and cancer. It aims to utilize the body’s own machinery – the T lymphocyte cell – to target and destroy can...
VASUDHA PHARMA CHEM LIMITED (VPCL) is a Company promoted by a team of accomplished technocrats for Bulk Drug industry with a total capital of Rupees 153 million ( US $ 5Million).All the promoters of V...
We have published hundreds of Immunocore Limited news stories on BioPortfolio along with dozens of Immunocore Limited Clinical Trials and PubMed Articles about Immunocore Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Immunocore Limited Companies in our database. You can also find out about relevant Immunocore Limited Drugs and Medications on this site too.
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...